OClawVPS.com
Xintela AB
Edit

Xintela AB

https://www.xintela.se/en/home
Tags:BioTechDevelopmentFacilityHealthTechManufacturingMedtechProductResearchTechnology
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
Location: Sweden, Lund
Member count: 11-50
Total raised: $939.788K
Founded date: 2009
LinkedIn
Email

Investors 1

DateNameWebsite
20.08.2022Flerie Inv...flerie.com

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
22.10.2013-$939.788K--

Mentions in press and media 16

DateTitleDescriptionCategoryAuthorSource
13.12.2021Xintela : ...Press release December 13, 20...--marketscre...
19.11.2021Xintela : ...Press release November 19, 20...--marketscre...
04.11.2021Update on ...Press release November 4, 202...--marketscre...
29.10.2021New board ...Press release October 29, 202...--marketscre...
12.10.2021Xintela : ...Archive Below you will find t...--marketscre...
30.09.2021Xintela : ...Lund, Sweden, September 30 202...--marketscre...
27.08.2021Xintela : ...Summary of the half-year repor...--marketscre...
14.07.2021Xintela : ...Archive Below you will find t...--marketscre...
21.05.2021XINTELA AB...Xintela announces today that t...--marketscre...
20.05.2021XINTELA AB...Xintela announces today that t...--marketscre...
Show more